| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Lawson and Flanigan), Pathology (Dr. Flanigan), Pediatrics (Dr. Flanigan), and Human Genetics (B.V. Graham and Dr. Flanigan), University of Utah School of Medicine, Salt Lake City.
Address correspondence and reprint requests to Dr Flanigan, University of Utah, Eccles Institute of Human Genetics, Rm 2100, 15 North 2030 East, Salt Lake City, UT 84132-2305; e-mail: kevin.flanigan{at}genetics.utah.edu
Background: Axonal neuropathy linked to the CMT2A locus was originally associated with a mutation in the KIF1B gene. However, mutations in this gene have not been described associated with any other CMT2A families. Recently, mutations in the MFN2 gene, encoding the mitochondrial GTPase mitofusin 2 (Mfn2), have been identified as causative of CMT2A in seven families. The authors report three additional CMT2A families associated with novel mutations in highly conserved regions of the Mfn2 GTPase domain.
Methods: The authors performed a standardized neuromuscular and nerve conduction examination, genotyped known CMT loci, and analyzed the MFN2 gene by direct sequencing in three pedigrees and 10 additional probands affected by axonal CMT.
Results: Sequencing of the MFN2 gene revealed a novel mutation in each family (c.818T>G, c.638T>C, and c.314C>T). The largest family demonstrated an age-independent variable expression such that approximately one quarter of individuals with the mutation presented with features mild enough as to remain occult even with electrophysiologic evaluation.
Conclusion: These results confirm that the majority of cases of CMT linked to the CMT2A locus are due to MFN2 mutations. The phenotype is largely indistinguishable from KIF1B-related CMT and from CMT2E and CMT2F. At least in some families, as many as 25% of individuals with MFN2 mutations may be asymptomatic and have a normal electrophysiologic examination, although a detailed neuromuscular examination may suggest the trait. Given the frequency of MFN2 mutations among CMT2 probands (3/13, or 23%), genetic testing of CMT2 patients should begin with a screen of the MFN2 gene.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the July 26 issue to find the title link for this article.
Editorial, see page 186
Supported by NIH NS42713-01 (V.H.L.), NIH M01 RR00064, and NIH C06-RR11234. V.H.L. is a past recipient of a CMT Association research fellowship.
Received November 4, 2004. Accepted in final form March 10, 2005.
Related articles in Neurology:
This article has been cited by other articles:
|
|
 |
|
  G. A. Nicholson, C. Magdelaine, D. Zhu, S. Grew, M. M. Ryan, F. Sturtz, J. -M. Vallat, and R. A. Ouvrier Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations Neurology, May 6, 2008; 70(19): 1678 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Detmer, C. V. Velde, D. W. Cleveland, and D. C. Chan Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A Hum. Mol. Genet., February 1, 2008; 17(3): 367 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Muglia, G Vazza, A Patitucci, M Milani, D Pareyson, F Taroni, A Quattrone, and M L Mostacciuolo A novel founder mutation in the MFN2 gene associated with variable Charcot Marie Tooth type 2 phenotype in two families from Southern Italy J. Neurol. Neurosurg. Psychiatry, November 1, 2007; 78(11): 1286 - 1287. [Full Text] [PDF]
|
|
|
|
|
|
H.M.E. Bienfait, F. Baas, J. H.T.M. Koelman, R. J. de Haan, B. G.M. van Engelen, A. A.W.M. Gabreels-Festen, B. W. Ongerboer de Visser, F. Meggouh, M. A.J. Weterman, P. De Jonghe, et al. Phenotype of Charcot-Marie-Tooth disease Type 2 Neurology, May 15, 2007; 68(20): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Detmer and D. C. Chan Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations J. Cell Biol., February 12, 2007; 176(4): 405 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Baloh, R. E. Schmidt, A. Pestronk, and J. Milbrandt Altered Axonal Mitochondrial Transport in the Pathogenesis of Charcot-Marie-Tooth Disease from Mitofusin 2 Mutations J. Neurosci., January 10, 2007; 27(2): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Verhoeven, K. G. Claeys, S. Zuchner, J. M. Schroder, J. Weis, C. Ceuterick, A. Jordanova, E. Nelis, E. De Vriendt, M. Van Hul, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2 Brain, August 1, 2006; 129(8): 2093 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Chung, S. B. Kim, K. D. Park, K. G. Choi, J. H. Lee, H. W. Eun, J. S. Suh, J. H. Hwang, W. K. Kim, B. C. Seo, et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations Brain, August 1, 2006; 129(8): 2103 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Griffin and D. C. Chan Domain Interactions within Fzo1 Oligomers Are Essential for Mitochondrial Fusion J. Biol. Chem., June 16, 2006; 281(24): 16599 - 16606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-P. Zhu, C. Soderblom, J.-H. Tao-Cheng, J. Stadler, and C. Blackstone SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development Hum. Mol. Genet., April 15, 2006; 15(8): 1343 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Reilly Axonal Charcot-Marie-Tooth disease: The fog is slowly lifting! Neurology, July 26, 2005; 65(2): 186 - 187. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
